2024 has seen significant advancements in bladder cancer treatment, with FDA approvals, new therapies, and clinical trials offering hope for patients, especially those with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
Ractigen Therapeutics' RAG-18, a small activating RNA (saRNA) therapy, has been granted Orphan Drug Designation by the FDA for treating Duchenne and Becker muscular dystrophy.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.